Your new experience awaits. Try the new design now and help us make it even better

MINI REVIEW article

Front. Cell Dev. Biol.

Sec. Cell Death and Survival

Volume 13 - 2025 | doi: 10.3389/fcell.2025.1650677

This article is part of the Research TopicImmunosenescence and Metabolic Reprogramming in Aging: Mechanistic Insights and InterventionsView all 4 articles

Immunosenescence and Metabolic Reprogramming in MASLD: An Age-Dependent Immunometabolic Vicious Cycle and Therapeutic Opportunities

Provisionally accepted
Yuxin  XuYuxin Xu1Qiuxiang  LiQiuxiang Li2Xuehua  JiaoXuehua Jiao1*
  • 1Department of Endocrinology, Suzhou Ninth People's Hospital, Suzhou, China
  • 2The Second Clinical Medical College, Nanjing Medical University, Nanjing, China

The final, formatted version of the article will be published soon.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) poses a disproportionately severe burden on the aging population, with a heightened risk of progression to advanced fibrosis and cancer. While immunosenescence and metabolic reprogramming are recognized as key drivers, this review proposes an age-dependent immunometabolic vicious cycle as a critical integrative framework underlying MASLD progression. We hypothesize that at the core of this cycle lies mitochondrial dysfunction and reactive oxygen species (ROS) accumulation, which may initiate a self-amplifying loop: triggering NLRP3 inflammasome activation in Kupffer cells, promoting a context-dependent dysfunction of adaptive immunity. This includes driving CD8⁺ T cells toward exhaustion in advanced disease and disrupting regulatory T cell (Treg) function, which may range from loss of suppressive capacity to a pro-fibrotic phenotypic switch. Together, these alterations in T cell immunity create a permissive environment for unchecked inflammation and fibrosis. This cycle is further reinforced by gut-liver axis dysfunction. Critically, this framework reveals that overcoming the therapeutic bottleneck in age-associated MASLD necessitates a paradigm shift toward combination therapies that simultaneously target multiple nodes of the cycle.

Keywords: metabolic dysfunction-associated steatotic liver disease (MASLD), immunosenescence, metabolic reprogramming, Vicious cycle, Mitochondrial dysfunction, combination therapy

Received: 20 Jun 2025; Accepted: 24 Sep 2025.

Copyright: © 2025 Xu, Li and Jiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Xuehua Jiao, xuehuajiaoszn@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.